Jacques N. Biot serves as the first utive chairman of Ecole Polytechnique since mid-2013, in the wake of an institutional reform passed to align the institution's by-laws with international standards. He has previously held positions as a senior advisor in the French administration, as a member of the utive committee of multinationals in the biopharma industry, as an entre-preneur with a focus on life sciences, as a Director in the board of a public company, as an investor in start-ups and as a non-utive chairman of the board of a Grande Ecole.
Biot's career has been focused on how to turn science and technology into economic value in a responsible way.
An Ecole Polytechnique graduate (Class of 71) and a member of the prestigious “Corps des Mines”, Biot initially served the French government, a typical career path in France for the elite of Polytechnique graduates. He dedicated his years in the administration to industry restructur-ing and innovation funding within the Ministry of Industry and Research. He then served as the advisor, in charge of “Industry and Technology” in the Prime Minister's office until 1985.
Subsequently, he held utive positions in highly innovative French biopharmaceutical com-panies, with a focus on strategy and international growth (Roussel Uclaf then Pasteur Merieux Serums and Vaccines, both later merged into the Sanofi Group).
From 1992 until mid-2012, he led an entrepreneurial career as the founder; chairman and CEO of a strategic consulting firm specialized in life sciences, where he recruited a multidisciplinary team dedicated to health technology assessment and market access. His client base was mas-sively international and included clients of all sizes in the pharma, biotech, medical technology, diagnostics, investment and health insurance industry. He has been invited as an expert in more than 30 pricing and reimbursement advisory boards and has been part of the faculty in more than 100 conferences on health technology assessment and European drug and med tech market access.
After successfully divesting his company, Biot played a role as an investor in start-ups in the healthcare field.
In parallel he has served since 2002 as an independent director, chairman of the audit commit-tee and finally deputy chairman of the Board of Guerbet Laboratories, a French public, family-owned company. Guerbet is one of the very few French firms in the biopharma industry having succeeded in obtaining an approval from the US FDA in 2012 for its lead drug, Dotarem, a contrast agent.
Biot has also for the last 10 years been a member of the scientific and technical commission of the Corps des Mines, which supervises PhD projects of young students. He also actively partici-pated, as Chairman of the Ecole des Mines d'Ales, in working parties in charge of designing the strategy of the
Ecoles des Mines and particularly in the formation of the Mines Telecom Institute.
He is a member of the commission "Innovation 2030". He was appointed in early 2014 to the International Board of the Moscow Institute for Physics and Technology, an institution wich has signed a strategic agreement with Polytechnique in August 2013. Since July 2014 he is member of the Board of Directors of the Institute d'Optique Graduate School.
Biot served as a member of the utive committee of the Kidney Forum, a citizens' initiative formed to foster best practices in the field of renal failure, a devastating disease.
A father of 3 daughters, Biot is fond of performing arts (opera, theater, ballet). He enjoys sailing, mountaineering, and flying. He has climbed several summits up to 20'700 feet. He holds a French and an Australian pilot license.
Biot is a member in the French Legion of Honor and officer in the French Order of Merit and a member of the Order of Lion of Senegal.